EUDA Health Holdings Limited (NASDAQ:EUDA) Short Interest Update

EUDA Health Holdings Limited (NASDAQ:EUDA) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 3,202 shares, a decrease of 38.7% from the June 15th total of 5,223 shares. Based on an average daily trading volume, of 5,978 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the shares of the stock are short sold.

EUDA Health Trading Down 9.1%

Shares of EUDA Health stock traded down $1.19 during trading hours on Friday, hitting $11.90. The company had a trading volume of 1,332 shares, compared to its average volume of 64,575. The company’s 50-day moving average is $15.05 and its two-hundred day moving average is $18.24. EUDA Health has a twelve month low of $5.26 and a twelve month high of $86.00.

EUDA Health (NASDAQ:EUDA) last posted its earnings results on Tuesday, May 5th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.76. The firm had revenue of $1.92 million during the quarter, compared to analysts’ expectations of $3.90 million. On average, equities analysts forecast that EUDA Health will post 1.6 EPS for the current fiscal year.

Hedge Funds Weigh In On EUDA Health

A hedge fund recently raised its position in EUDA Health stock. Citadel Advisors LLC increased its stake in shares of EUDA Health Holdings Limited (NASDAQ:EUDA) by 57.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,631 shares of the company’s stock after purchasing an additional 16,321 shares during the quarter. Citadel Advisors LLC owned 0.12% of EUDA Health worth $78,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 4.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Zacks Research upgraded EUDA Health from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. Weiss Ratings downgraded EUDA Health from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $55.00.

EUDA Health Company Profile

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.